Business Wire

NY-AQARA

3.11.2022 09:01:35 CET | Business Wire | Press release

Share
Aqara Releases Details Around Its First Matter-Compatible Devices

Aqara, a leading provider for smart home products, shares its latest plan of Matter support and integration for its existing and new devices. Aqara is fully committed to supporting Matter, and the Company has been working with the Connectivity Standards Alliance (CSA) and key stakeholders such as Apple, Google and Samsung on early testing programs to ensure a smooth transition towards the new standard. Aqara users will first gain access to Matter in December 2022 via the Aqara Hub M2 through an OTA (over-the-air) update, which will allow existing Aqara Zigbee devices to become compatible with Matter.

Other Aqara hubs, including the Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3, and Camera Hub G2H Pro, will also receive similar OTA updates in the following months so that more Aqara users will be able to enjoy the benefits of Matter. The software updates are expected to first expose more than 40 Aqara Zigbee devices ranging from smart sensors and wireless switches to controller-type devices such as radiator thermostats and curtain controllers*. Through the Aqara hubs, these devices will be able to support Matter and connect with other third-party Matter devices. Some of these devices are listed below:

  • Door & Window Sensor
  • Temperature & Humidity Sensor
  • Motion Sensor and Motion Sensor P1
  • Vibration Sensor
  • Smart Wall Switch (US)
  • Smart Wall Switch H1 EU
  • Smart Plug (US & EU)
  • Single Switch Module T1
  • Wireless Mini Switch
  • Wireless Remote Switch H1
  • Wireless Remote Switch (Single & Double Rocker)
  • Radiator Thermostat E1
  • Roller Shade Driver E1
  • Curtain Driver E1
  • Roller Shade Controller (Zigbee 1.2)
  • LED Bulb and LED Bulb T1 (Tunable White)

Aqara aims to provide a comprehensive suite of Matter-compatible devices to global users, and its Matter device portfolio will continue to grow and incorporate other existing Zigbee devices in the coming future. Ultimately more than 160 Aqara Zigbee products belonging to over 10 different device categories are expected to receive Matter support.

Moreover, a new lineup of Thread-based devices will be introduced. Building upon the success of Aqara’s iconic door and window sensor as well as the motion sensor, the Company will refresh the designs of these two devices to adopt the Thread protocol - among other enhancements - to allow for native Matter support and direct connection with Matter controllers. The new sensors, i.e. the Door and Window Sensor P2 and the Motion and Light Sensor P2, are set to release in early 2023. As part of the ongoing partnership between NXP Semiconductors and Aqara, the Aqara Thread sensor will be showcased at the NXP demo table on the Matter launch event in Amsterdam.

An array of Thread-based Aqara devices is to follow including various smart sensors, dimmer switches, smart plugs, lights, and the next-gen smart home hub with multi-protocol support. The Aqara Hub M3 is designed to not only allow Aqara Zigbee devices to support Matter, but also serve as a Thread Border Router and a Matter Controller and Commissioner, which can directly connect and manage Thread and Matter-compatible smart home devices. The Company also plans to open its Aqara Home app to support third-party Matter devices.

Aqara strives to offer high-quality, smart home solutions that are accessible to everyone, specifically focusing on creating a seamless user experience. The Matter standard undoubtedly raises connected home experiences to the next level with unprecedented interoperability and simplicity, and Aqara will continue to enrich its Matter portfolio to offer users even more options for their smart homes and to expedite the mass adoption of smart homes worldwide.

* A full list of the first Aqara Zigbee devices to receive Matter support is available here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005123/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye